In 2008, the U.S [[Food and Drug Administration]] (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint or muscle pain.<ref>{{Cite web|url=http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124165.htm|title=Information for Healthcare Professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)|publisher=U.S. Food and Drug Administration|accessdate=27 October 2010}}</ref> A study conducted by the American Society of Bone and Mineral Research concluded that long-term use of [[bisphosphonates]], including Boniva, may increase the risk of a rare but serious fracture of the femur.

 
<ref>{{Cite web|url=http://www.asbmr.org/about/pressreleases/detail.aspx?cid=a68f2b70-a117-4094-9f6f-b5993c6a6149|title=Drugs Commonly Prescribed for Osteoporosis Patients are Effective at Reducing Risk of Hip and Spine Fractures, But Panel Says May be Related to Unusual Thigh Bone Fractures When Used Long Term |publisher=Journal of Bone and Mineral Research=27 October 2010}}</ref>

 

